Shares of Waldencast plc (NASDAQ:WALD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $5.11.
Several research firms have weighed in on WALD. DA Davidson reaffirmed a “buy” rating and issued a $7.50 price target on shares of Waldencast in a research note on Wednesday, March 19th. Telsey Advisory Group decreased their target price on Waldencast from $5.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, May 15th. Alliance Global Partners reiterated a “buy” rating on shares of Waldencast in a report on Thursday. Canaccord Genuity Group decreased their price objective on Waldencast from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, May 15th. Finally, Industrial Alliance Securities set a $5.00 target price on Waldencast in a research report on Tuesday, April 22nd.
Read Our Latest Research Report on Waldencast
Institutional Trading of Waldencast
Waldencast Trading Up 0.5%
NASDAQ:WALD opened at $2.12 on Friday. Waldencast has a twelve month low of $1.98 and a twelve month high of $5.21. The company has a fifty day moving average of $2.77 and a 200-day moving average of $3.17. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.21.
Waldencast Company Profile
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
Recommended Stories
- Five stocks we like better than Waldencast
- The 3 Best Blue-Chip Stocks to Buy Now
- UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?
- What is a SEC Filing?
- What Ray Dalio’s Latest Moves Tell Investors
- Consumer Staples Stocks, Explained
- Amazon: Why May Is the Last Month to Get the Stock at a Discount
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.